Short Interest in Regen BioPharma, Inc. (OTCMKTS:RGBP) Rises By 30.8%

Regen BioPharma, Inc. (OTCMKTS:RGBP) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 1,700 shares, a growth of 30.8% from the December 15th total of 1,300 shares. Based on an average daily volume of 100,800 shares, the short-interest ratio is currently 0.0 days.

Regen BioPharma Stock Performance

Regen BioPharma stock traded up $0.01 during mid-day trading on Friday, hitting $0.07. The company’s stock had a trading volume of 2,394 shares, compared to its average volume of 13,890. The business has a 50 day moving average price of $0.08 and a 200-day moving average price of $0.28. Regen BioPharma has a 12 month low of $0.02 and a 12 month high of $0.60.

Regen BioPharma Company Profile

Regen BioPharma, Inc focuses on the development of regenerative medical applications in the United States. It engages in identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is involved in the development of its products, and therapies, including HemaXellarate, a cellular therapeutic product of autologous stromal vascular fraction derived from adipose tissue; dCellVax, an autologous dendritic cell which is treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax which is treated with siRNA to inhibit NR2F6 and the cells re-infused to the patient; DiffronC, uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuroCAR comprising of CAR-T cells which is treated with an shRNA targeting the gene NR2F6.